We are a team of experienced physicians, biotechnologists, and scientists with over 20 years of expertise in both classical medicine and stem cell therapy.
Regeniq— an innovative medical center that develops personalized treatment programs based on stem cells. We combine advanced scientific research with an individual approach to restore health and improve quality of life.
Our core medical team achieved an average of 20 years of professional experience in clinical medicine and regenerative therapies.
Our team includes 22 highly qualified physicians, each bringing extensive expertise and a strong commitment to delivering exceptional patient care.
The Outré Clinic project was launched, combining advanced medical diagnostics with pioneering stem cell applications.
We established our own biotechnology laboratory, Regeniq, dedicated to the research, production, and advancement of high-quality stem cell therapeutics.
Internal Medicine Program Lead
Supports patients through comprehensive medical assessments, with a focus on overall health and wellbeing. Responsible for prescribing diagnostic tests, reviewing laboratory results, imaging studies, and multidisciplinary reports. Provides guidance on chronic condition management and preventive care.
Director of the Stem Cell Biosafety and Scientific Research Department
Dmytro Havrylei is a seasoned expert in biochemistry, medicine, and biotechnology with over 20 years of experience in laboratory development, diagnostic systems implementation, and biotech project management. His expertise includes the development and application of biologics with a strong focus on biosafety, as well as the successful execution of public health programs in collaboration with international organizations.
Neurosurgeon and Biotechnologist Stem Cell Manufacturing Division
Jiang Long is a neurosurgeon and PhD in Medical Sciences with over 10 years of clinical experience in Ukraine, specializing in neuro-oncology, neurotrauma, and emergency surgery. He has hands-on experience in the clinical application of stem cell therapies, is the author of 18 scientific publications, and holds two medical patents, actively engaged in research and international collaboration in the field of regenerative medicine.
Strategic Advisor for International Cooperation
Ihor Dir — Ambassador Extraordinary and Plenipotentiary of Ukraine, international legal expert, and advisor to the Chairman of the Board of Ukrgasbank. With decades of diplomatic experience, he has represented Ukraine in key negotiations with the EU, WTO, EBRD, and WHO, contributing to strategic international agreements and development initiatives.
Ophthalmologist, Clinical Development Advisor
Ophthalmologist with over 25 years of clinical and surgical experience in Saudi Arabia and Ukraine. Specializes in comprehensive eye care and ophthalmic surgery, with a long-standing reputation for professional excellence. As Clinical Development Advisor at Regeniq, he contributes his expertise to the advancement of clinical practices and supports the team in shaping innovative therapeutic approaches.
Targeted Regeneration with Regeniq Cells
The Regeniq Basic Program delivers focused, precision-based regenerative therapy using organ-specific fetal stem cells and clinically formulated fetal bioconcentrates. This protocol is optimized for localized or early-stage conditions where strategic cellular restoration provides the highest therapeutic yield.
Each protocol includes two types of fetal-derived stem cells tailored to the patient’s condition — for instance, hepatic cells for liver dysfunction or cardiomyocytes for myocardial restoration. Fetal tissue bioconcentrates, rich in cytokines, growth factors, and signaling peptides, further enhance the regenerative cascade and cellular communication.
Integrated Multisystem Regeneration
The Regeniq Standard Program introduces a multi-axis regenerative strategy combining three synergistic stem cell lines: organ-specific fetal cells (Includes 3 types of stem cells selected for the patient`s primary condition), endothelial stem cells, and neural stem cells. This protocol addresses both localized tissue repair and systemic revitalization — particularly of the vascular and neurocognitive systems, which govern aging, energy regulation, and stress resilience.
All stem cell treatments are supported by fetal-derived bioconcentrates that prime the body’s internal environment for optimized cellular uptake, immune harmonization, and accelerated recovery.
Full-Spectrum Cellular Reset with Regeniq
Regeniq’s Advanced Program is our most comprehensive and scientifically robust regenerative solution. Built on the integration of fetal stem cells from all three embryonic germ layers (ectoderm, mesoderm, endoderm), this protocol offers near-pluripotent regenerative potential across virtually all tissue types. While each cell is already multipotent, collectively they provide pluripotent-level regenerative potential across all major organs and systems-giving them the ability to differentiate into 200 cell types of the human body.
Combined with an enriched matrix of fetal-derived exosomes, microRNAs, cytokines, peptides, and growth factors, this program initiates a cascade of intercellular communication and systemic healing, restoring balance on a molecular and cellular level.
Fully Customized Regenerative Pathways
Regeniq’s Personalized Program offers complete flexibility for patients with unique therapeutic goals, complex diagnostic profiles, or specific treatment constraints.
Every aspect of the treatment — from stem cell selection to dosing schedules and bioconcentrate composition — is designed around the individual. Whether the priority is budget, timeline, combination therapies, or targeted outcomes, this program provides precision without compromise.
All protocols are developed by our clinical and biotechnology teams in conjunction with in-depth diagnostic analytics and physician consultation.
A flagship biopharmaceutical containing all major types of fetal stem cells from a single donor
Fetal cardiogenic progenitors capable of regenerating heart tissue and vascular structures, with high integration potential.
Neuroectodermal stem cells derived from fetal brain tissue with high capacity for neurogenesis and glial regeneration.
Multipotent fetal placental stem cells with systemic regulatory effects on immunity, hormones, and cellular repair.
Cell-free extract from fetal brain tissue enriched with neurotrophic peptides, cytokines, and microvesicles.
We utilize stem cells derived from primary fetal organs to treat the corresponding organs of the patient. This targeted approach ensures effective restoration and regeneration of damaged tissues in the heart, liver, lungs, nervous system, and other vital systems of the body.
Our programs incorporate neural and endothelial stem cells, contributing to the rejuvenation of the cardiovascular and nervous systems. This holistic approach not only treats diseases but also significantly improves overall health and slows down the aging process.
Regeniq operates at the forefront of modern biotechnology, leveraging methods of cellular therapy, tissue engineering and molecular biology. Our approaches are grounded in the latest scientific research and adhere to the standards of WHO, EMA CAT, and FDA.
Our team consists of experts with years of experience in stem cell therapy and regenerative medicine. We strictly follow international treatment protocols, ensuring high levels of safety and effectiveness at every stage of therapy
Fetal stem cells are obtained from human fetal tissues between 8–12 weeks of development. Unlike adult cells (such as mesenchymal stem cells), they have higher plasticity, greater proliferative capacity, and broader differentiation potential.
Yes, when conducted under strict medical and biosafety protocols. All cells are screened for infections and genetic abnormalities. Due to their low immunogenicity, fetal cells do not trigger acute rejection and do not require immunosuppression.
They are used to treat neurodegenerative diseases (such as dementia and Parkinson’s), autoimmune disorders, diabetes, chronic fatigue, post-COVID syndrome, and are also applied in systemic anti-aging and post-oncology recovery programs.
Fetal cells divide more rapidly, secrete more growth factors, exosomes, and signaling molecules, and have a younger biological age — making them more potent in tissue repair and regeneration.
They are obtained from legally terminated pregnancies with informed donor consent and under strict ethical and legal oversight. All tissues are processed according to biosafety and clinical quality standards.
Cells are administered intravenously and, if needed, locally (e.g., into joints or the spinal canal). Each protocol is personalized and may include multiple sessions depending on the diagnosis.
Most patients begin to notice improvements within 3-6 months. The therapeutic effect is gradual and may continue for 6–12 months as the introduced cells stimulate ongoing regeneration.
No. Most treatments are outpatient procedures conducted under medical supervision. Hospitalization is only needed in complex cases or intensive combined protocols.
Basic protocols typically last 3 to 6 days. More advanced or personalized programs vary depending on the patient’s condition and therapeutic goals.
Yes. Numerous clinical and preclinical studies confirm the effectiveness of fetal cells in tissue regeneration, immune modulation, and functional restoration in chronic diseases.
Unlock the potential of advanced stem cell therapy with Regeniq. Our specialists are ready to guide you through personalized treatment options tailored to your health goals.
Contact us today for a consultation and take the
first step towards rejuvenation and recovery.
